Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Regeneron is a fully integrated biotechnology company inventing, developing, manufacturing, and commercializing medicines for serious diseases, including eye diseases, allergic and inflammatory diseases, cancer, and rare diseases. The company operates as a single business segment.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenues | $14,342.9 | $14,202.0 | $13,117.2 |
| Net Income | $4,504.9 | $4,412.6 | $3,953.6 |
| Diluted EPS | $41.48 | $38.34 | $34.77 |
| Operating Cash Flow | $4,978.9 | $4,420.5 | $4,594.0 |
| Net Product Sales | $6,309.1 | $7,629.2 | $7,078.0 |
| Collaboration Revenue | $7,331.2 | $6,057.8 | $5,503.1 |
| Long-Term Debt | $1,985.9 | $1,984.4 | N/A |
| Cash and Cash Equivalents | $3,118.1 | $2,488.2 | N/A |
| Working Capital | $13,653.5 | $14,716.6 | N/A |
Gross Margin on Net Product Sales: 82% in 2025 (down from 86% in 2024).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 1% to $14.3 billion, driven primarily by a 30% increase in Sanofi collaboration revenue (largely due to Dupixent sales) and growth in EYLEA HD U.S. sales.
- Product Sales Decline: Net product sales recorded by Regeneron decreased 17% to $6.3 billion. This was primarily due to a 42% decline in U.S. EYLEA sales caused by biosimilar competition, patient transition to EYLEA HD, and affordability constraints.
- EYLEA HD Growth: U.S. net product sales for EYLEA HD increased 36% to $1.6 billion, partially offsetting the decline in EYLEA.
- Operating Expenses: Total operating expenses increased 5% to $10.8 billion. Research and development (R&D) expenses rose 14% to $5.9 billion, including a $155 million charge for a Priority Review Voucher utilized in Q4 2025.
- Other Income: Other income increased significantly to $1.7 billion (from $0.8 billion in 2024), driven by a $946 million net gain on marketable and other securities.
- Tax Rate: The effective tax rate increased to 13.9% in 2025 from 7.7% in 2024, impacted by the "One Big Beautiful Bill Act" (OBBBA) and a lower benefit from stock-based compensation.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Product Pipeline: Management highlighted progress in clinical programs, including positive Phase 3 data for itepekimab in COPD (one trial met primary endpoint, one did not) and birch/cat allergy treatments. Regulatory approvals were received for EYLEA HD for RVO and every 4-week dosing.
- Manufacturing: A new fill/finish facility in Rensselaer, NY, is undergoing process validation. The company expects capital expenditures of $1.1–$1.3 billion in 2026.
- Dividends and Buybacks: The company initiated a quarterly cash dividend program in 2025 ($0.88/share) and declared a $0.94/share dividend in January 2026. As of year-end, $1.486 billion remained available under the share repurchase program.
Risks and Contingencies
- Biosimilar Competition: EYLEA faces significant competition from biosimilars in the U.S. and globally. Several biosimilars have launched or are expected to launch in 2026, which may further impact EYLEA sales.
- Regulatory Delays: The FDA issued Complete Response Letters (CRLs) for the EYLEA HD pre-filled syringe and Ordspono (odronextamab) in 2025 due to unresolved inspection findings at a third-party manufacturer (Catalent). Resubmissions are pending.
- Legal Proceedings:
- EYLEA Litigation: Ongoing patent infringement lawsuits and post-grant proceedings globally. Settlements reached in 2025/2026 with several biosimilar developers (Mylan, Biocon, Sandoz, Celltrion, Samsung Bioepis, Alvotech) delay their launches until 2026.
- Government Investigations: Civil proceedings initiated by the U.S. Department of Justice regarding patient assistance programs and pricing reporting (False Claims Act).
- Sanofi Litigation: Regeneron sued Sanofi in late 2024 alleging breach of collaboration agreement regarding access to commercialization data for Dupixent.
- Manufacturing Supply Chain: Reliance on third-party manufacturers for fill/finish services creates supply chain risks, as evidenced by recent FDA inspection issues.
Unusual Items
- Priority Review Voucher (PRV): A $155 million charge was recorded in R&D expenses in Q4 2025 after the company decided to utilize a PRV purchased earlier in the year for a regulatory submission.
- Acquired IPR&D: Included an $80 million upfront payment for a license agreement with Hansoh Pharmaceuticals for a GLP-1/GIP receptor agonist.
Important Facts for Investor Verification
- EYLEA Sales Trajectory: Verify the extent of market share loss for EYLEA to biosimilars and compounded bevacizumab, and the rate of patient transition to EYLEA HD.
- Sanofi Collaboration Profitability: Confirm the sustainability of the profit-sharing model with Sanofi, particularly given the ongoing litigation regarding data access and the contingent reimbursement obligation of ~$595 million.
- Regulatory Resolutions: Monitor the status of FDA decisions on the resubmitted EYLEA HD pre-filled syringe application and the Ordspono BLA, as these are critical for future revenue growth.
- Legal Exposure: Assess the potential financial impact of the Department of Justice investigations regarding pricing and patient assistance, as well as the outcome of the Sanofi breach of contract lawsuit.
- Manufacturing Capacity: Verify the timeline for the approval of the new Rensselaer fill/finish facility and the resolution of supply chain issues with third-party manufacturers.